Photo of Konrad H. Stopsack, MD, MPH

Konrad H. Stopsack, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital


kstopsack@mgh.harvard.edu

Photo of Konrad H. Stopsack, MD, MPH

Massachusetts General Hospital


kstopsack@mgh.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Konrad H. Stopsack, MD, MPH but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Konrad H. Stopsack, MD, MPH

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a clinical and molecular epidemiologist with a focus on cancer epidemiology. My interdisciplinary research program assesses causes and outcomes of solid tumors, particularly prostate cancer. With my prior background as a board-certified internal medicine physician, I am passionate about combining well-defined observational studies and state-of-the-art genomics in order to guide cancer prevention and treatment. My methodology interests include application and further development of epidemiologic methods in clinical studies and -omics research.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Rajanala SH, Plym A, Vaselkiv JB, Ebot EM, Matsoukas K, Lin Z, Chakraborty G, Markt SC, Penney KL, Lee GM, Mucci LA, Kantoff PW, Stopsack KH. SLCO1B3 and SLCO2B1 Genotypes, Androgen Deprivation Therapy, and Prostate Cancer Outcomes: A Prospective Cohort Study and Meta-analysis. Carcinogenesis 2023. PubMed
  • Darst BF, Saunders E, Dadaev T, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Wang Y, Patel AV, Albanes D, Weinstein SJ, Gnanapragasam V, Huff C, Couch FJ, Wolk A, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz MM, Schmidt JA, Travis RC, Key TJ, Stopsack KH, Mucci LA, Catalona WJ, Marosy B, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Conti DV, Kote-Jarai Z, Haiman CA. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. JAMA Oncol 2023. PubMed
  • Ma C, Wang X, Dai JY, Turman C, Kraft P, Stopsack KH, Loda M, Pettersson A, Mucci LA, Stanford JL, Penney KL. Germline genetic variants associated with somatic TMPRSS2:ERG fusion status in prostate cancer: a genome-wide association study. Cancer Epidemiol Biomarkers Prev 2023. PubMed
  • Stopsack KH, Mucci LA, Giovannucci EL. Aggressive Prostate Cancer Is Preventable and so Are Racial Disparities. J Clin Oncol 2023. PubMed
  • Rencsok EM, Stopsack KH, Slopen N, Odedina FT, Ragin C, Nowak J, McSwain L, Manarite J, Heath E, George DJ, Kantoff PW, Vinson J, Villanti P, Haneuse S, Mucci LA, . Experience with the US health care system for Black and White patients with advanced prostate cancer. Cancer 2023. PubMed
  • Iyer HS, Kensler KH, Vaselkiv JB, Stopsack KH, Roscoe C, Bandera EV, Qin B, Jang TL, Lotan TL, James P, Hart JE, Mucci LA, Laden F, Rebbeck TR. Associations between etiologic or prognostic tumor tissue markers and neighborhood contextual factors in male health professionals diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev 2023. PubMed
  • Iyer HS, Vaselkiv JB, Stopsack KH, Roscoe CJ, DeVille NV, Zhang Y, Penney KL, Balk SP, Fiorentino M, Hart JE, James P, De Vivo I, Mucci LA, Laden F, Rebbeck TR. Influence of neighborhood social and natural environment on prostate tumor histology in a cohort of male health professionals. Am J Epidemiol 2023. PubMed
  • Stopsack KH, Plym A, Mucci LA. The Imperative for Population-based Cancer Registration of All Metastatic Cancers. Cancer Epidemiol Biomarkers Prev 2023; 32:585-587. PubMed
  • Stopsack KH, Mucci LA, Tworoger SS, Kang JH, Eliassen AH, Willett WC, Stampfer MJ. Promoting reproducibility and integrity in observational research: one approach of an epidemiology research community. Epidemiology 2023. PubMed
  • Ma W, Murray E, Nguyen LH, Drew DA, Ding M, Stopsack KH, Rich-Edwards JW, Hart JE, Figueiredo JC, Lacey JV, Patel AV, Bhupathiraju SN, Chan AT, Martinez ME. Physical Activity, Sedentary Behavior, and Risk of Coronavirus Disease 2019. Am J Med 2023. PubMed
  • Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL. The prostate stromal transcriptome in aggressive and lethal prostate cancer. Mol Cancer Res 2022. PubMed
  • Zhang Y, Stopsack KH, Wu K, Song M, Mucci LA, Giovannucci E. Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer. J Urol 2022. PubMed
  • Alshalalfa M, Nguyen TT, Stopsack KH, Khan A, Franco I, Seldon C, Swami N, Jin W, Meiyappan K, Ton M, Venstrom JM, Dee EC, Mahal BA. Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis. Urol Oncol 2022. PubMed
  • Arora K, Tran TN, Kemel Y, Mehine M, Liu YL, Nandakumar S, Smith SA, Brannon AR, Ostrovnaya I, Stopsack KH, Razavi P, Safonov A, Rizvi HA, Hellmann MD, Vijai J, Reynolds TC, Fagin JA, Carrot-Zhang J, Offit K, Solit DB, Ladanyi M, Schultz N, Zehir A, Brown CL, Stadler ZK, Chakravarty D, Bandlamudi C, Berger MF. Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort. 2022; 12:2552-2565. PubMed
  • Mucci LA, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH, Hyslop T, Villanti P, Kantoff PW, George DJ, . IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. JCO Glob Oncol 2022; 8:e2200154. PubMed
  • Ghalali A, Wang L, Stopsack KH, Rice JM, Wu S, Wu CL, Zetter BR, Rogers MS. AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer. Exp Mol Med 2022; 54:1713-1726. PubMed
  • Zhou CD, Pettersson A, Plym A, Tyekucheva S, Penney KL, Sesso HD, Kantoff PW, Mucci LA, Stopsack KH. Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? Cancer Prev Res (Phila Pa) 2022. PubMed
  • Stopsack KH, Su XA, Vaselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, Fiorentino M, Loda M, Penney KL, Lotan TL, Mucci LA. Transcriptomes of prostate cancer with TMPRSS2:ERG and other ETS fusions. Mol Cancer Res 2022. PubMed
  • Barnett ES, Schultz N, Stopsack KH, Lam ET, Arfe A, Lee J, Zhao JL, Schonhoft JD, Carbone EA, Keegan NM, Wibmer A, Wang Y, Solit DB, Abida W, Wenstrup R, Scher HI. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2022. PubMed
  • Plym A, Zhang Y, Stopsack KH, Jee YH, Wiklund F, Kibel AS, Kraft P, Giovannucci E, Penney KL, Mucci LA. Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years. Clin Cancer Res 2022. PubMed
  • Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Mol Oncol 2022. PubMed
  • Wang A, Xu Y, Yu Y, Nead KT, Kim T, Xu K, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, Stevens V, Albanes D, Weinstein SJ, Gnanapragasam V, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz MM, Schmidt JA, Stopsack KH, Mucci LA, Catalona WJ, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Kote-Jarai Z, de Smith AJ, Conti DV, Huff C, Haiman CA, Darst BF. Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. Hum Mol Genet 2022. PubMed
  • Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N, Kantoff PW. The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer. Clin Cancer Res 2022. PubMed
  • Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C, Kenfield SA, Kibel AS, Giovannucci E, Penney KL, Mucci LA. A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. Eur Urol 2022. PubMed
  • Craig EL, Stopsack KH, Evergren E, Penn LZ, Freedland SJ, Hamilton RJ, Allott EH. Statins and prostate cancer-hype or hope? The epidemiological perspective. Prostate Cancer Prostatic Dis 2022; 25:641-649. PubMed
  • Vaselkiv JB, Ceraolo C, Wilson KM, Pernar CH, Rencsok EM, Stopsack KH, Grob ST, Plym A, Giovannucci EL, Olumi AF, Kibel AS, Preston MA, Mucci LA. 5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiol Biomarkers Prev 2022. PubMed
  • Ozcan Z, Lucas FAS, Wong JW, Chang K, Stopsack KH, Fowler J, Jakubek YA, Scheet P. Chromosomal imbalances detected via RNA-sequencing in 28 cancers. Bioinformatics 2022; 38:1483-90. PubMed
  • Keegan NM, Vasselman SE, Barnett ES, Nweji B, Carbone EA, Blum A, Morris MJ, Rathkopf DE, Slovin SF, Danila DC, Autio KA, Scher HI, Kantoff PW, Abida W, Stopsack KH. Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. Prostate 2022; 82:1107-1116. PubMed
  • Stopsack KH, Salles DC, Vaselkiv JB, Grob ST, Mucci LA, Lotan TL. p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up. Eur Urol Oncol 2021. PubMed
  • Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE, Slovin SF, Danila DC, Autio KA, Scher HI, Mucci LA, Solit DB, Gonen M, Chen Y, Berger MF, Schultz N, Abida W, Kantoff PW. Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res 2021. PubMed
  • Stopsack KH. Editorial Comment. J Urol 2021; 205:1378. PubMed
  • Stopsack KH. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing P Eur Urol 2021; 79:e81-e82. PubMed
  • Pan W, Zhang Z, Kimball H, Qu F, Berlind K, Stopsack KH, Lee GM, Choueiri TK, Kantoff PW. Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. Clin Cancer Res 2021. PubMed
  • Allott EH, Craig EL, Stopsack KH. In search of the optimal setting for statin trials in prostate cancer: the power of population-based studies. Prostate Cancer Prostatic Dis 2021; 24:583-584. PubMed
  • Stopsack KH. Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health? Eur Urol 2021; 79:453-455. PubMed
  • Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. Elife 2021. PubMed
  • Stopsack KH. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol 2021; 79:442-445. PubMed
  • Drago JZ, Gönen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH. Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. Journal of the National Cancer Institute 2021; 113:553-561. PubMed
  • Chakraborty G, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in -altered Prostate Tumors. Clin Cancer Res 2020. PubMed
  • Nguyen B, Mota JM, Nandakumar S, Stopsack KH, Weg E, Rathkopf D, Morris MJ, Scher HI, Kantoff PW, Gopalan A, Zamarin D, Solit DB, Schultz N, Abida W. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. Eur Urol 2020; 78:671-679. PubMed
  • Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Wu L, Jacobs EJ, Mucci LA, Platz EA, Cook MB, . Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research. Journal of the National Cancer Institute 2020. PubMed
  • Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol 2020; 78:637-639. PubMed
  • Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, Mucci LA, Loda M. Multiplex immunofluorescence in formalin-fixed paraffin-embedded tumor tissue to identify single cell-level PI3K pathway activation. Clin Cancer Res 2020. PubMed
  • Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis 2020. PubMed
  • Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH, Stopsack KH, Ebot EM, Fu BC, Zhang Y, Li N, Dai M, Liu L, Giovannucci EL, Mucci LA. The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer 2020. PubMed
  • Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precis Oncol 2020; 4:355-366. PubMed
  • Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 2020; 52:1219-1226. PubMed
  • Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. and COVID-19: Serendipity or Opportunity for Intervention? 2020; 10:779-782. PubMed
  • Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, Kim CJ, Carbone EA, Vasselman SE, Nguyen B, Hullings MA, Scher HI, Morris MJ, Solit DB, Schultz N, Kantoff PW, Abida W. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res 2020; 26:3230-3238. PubMed
  • Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin Cancer Res 2019. PubMed
  • Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res 2019. PubMed
  • Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A 2019; 116:11390-11395. PubMed
  • Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA, Kantoff PW. Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2019. PubMed
  • Stopsack KH, Gerke T, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, Mucci LA, Kantoff PW. Low expression of the androgen-induced tumor suppressor gene PLZF and lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2019. PubMed
  • Stopsack KH, Cerhan JR. Cumulative Doses of Ionizing Radiation From Computed Tomography: A Population-Based Study. Mayo Clin. Proc. 2019; 94:2011-2021. PubMed
  • Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res 2018. PubMed
  • Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur Urol 2018. PubMed
  • Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, Lis RT, Graff RE, Pettersson A, Pernar CH, Loda M, Kantoff PW, Ahearn TU, Mucci LA, . A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status. Cancer Epidemiol Biomarkers Prev 2018; 27:1231-1233. PubMed
  • Xie W, Stopsack KH, Drouin SJ, Fu H, Pomerantz MM, Mucci LA, Lee GM, Kantoff PW. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate 2018. PubMed
  • Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA. Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes Control 2018. PubMed
  • Brauner A, Alvendal C, Chromek M, Stopsack KH, Ehrström S, Schröder JM, Bohm-Starke N. Psoriasin, a novel anti-Candida albicans adhesin. J Mol Med 2018; 96:537-545. PubMed
  • Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis 2017. PubMed
  • Bormann T, Stopsack KH, Mader I, Weiller C, Rijntjes M. A formal analysis of alexia in persistent aura and a comparison to acquired pure alexia. Neurocase 2017; 23:60-64. PubMed
  • Weidler S, Stopsack KH, Hammermann J, Sommerburg O, Mall MA, Hoffmann GF, Kohlmüller D, Okun JG, Macek M, Votava F, Krulišová V, Balaščaková M, Skalická V, Lee-Kirsch MA, Stopsack M. A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening. 2016; 15:752-758. PubMed
  • Stopsack KH, Greenberg AJ, Mucci LA. Common medications and prostate cancer mortality: a review. World J Urol 2016. PubMed
  • Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol metabolism and prostate cancer lethality. Cancer Res 2016. PubMed
  • Stopsack KH, Vinod Shah M. Bilateral Foot Gangrene. JAMA Oncol 2016; 2:387-8. PubMed
  • Kekre N, Mak KS, Stopsack KH, Binder M, Ishii K, Brånvall E, Cutler CS. Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. Am J Hematol 2016. PubMed
  • Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control 2015. PubMed
  • Ramos NL, Dzung DT, Stopsack K, Jankó V, Pourshafie MR, Katouli M, Brauner A. Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries. 2011; 30:1587-93. PubMed
  • Vogelberg C, Stensvold CR, Monecke S, Ditzen A, Stopsack K, Heinrich-Gräfe U, Pöhlmann C. Blastocystis sp. subtype 2 detection during recurrence of gastrointestinal and urticarial symptoms. 2010; 59:469-71. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Konrad H. Stopsack, MD, MPH but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members